Self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles

Vaccines

Volumn 2, Issue 4, 2014, Pages 735-754

  McCullough, Kenneth C ^a   Milona, Panagiota ^a   Thomann Harwood, Lisa ^a   Démoulins, Thomas ^a   Englezou, Pavlos ^a   Suter, Rolf ^b   Ruggli, Nicolas ^a  

^a INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

^b MICROSYNTH AG   (Switzerland)

Author keywords

Nanoparticle delivery; Self replicating replicon RNA; Targeting dendritic cells

Indexed keywords

ANTIGEN; CHOLESTEROL; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOUBLE STRANDED RNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; NANOPARTICLE; NUCLEIC ACID; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RNA VACCINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7;

ACIDIFICATION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENDOSOME; GENE; IMMUNE RESPONSE; IMMUNITY; IMMUNOREGULATION; NONHUMAN; REPLICON; REVIEW; RNA INTERFERENCE; RNA TRANSLATION;

EID: 84908239334     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2040735     Document Type: Review

References (101)

1. McCullough, K.C.; Bassi, I.; Demoulins, T.; Thomann-Harwood, L.J.; Ruggli, N. Functional RNA delivery targeted to dendritic cells by synthetic nanoparticles. Ther. Deliv. 2012, 3, 1077-1099.
2. Thomann-Harwood, L.J.; Kaeuper, P.; Rossi, N.; Milona, P.; Herrmann, B.; McCullough, K.C. Nanogel vaccines targeting dendritic cells: Contributions of the surface decoration and vaccine cargo on cell targeting and activation. J. Control. Release 2013, 166, 95-105.
3. Fearon, D. Happy coupling: Recruiting both antigen and effector function. Nat. Biotechnol. 1997, 15, 618-619.
4. Janeway, C. Immunogenicity signals 1,2,3… and 0. Immunol. Today 1989, 10, 283-286.
5. Pulendran, B.; Ahmed, R. Translating innate immunity into immunological memory: Implications for vaccine development. Cell 2006, 124, 849-863.
6. Atkins, G.J.; Fleeton, M.N.; Sheahan, B.J. Therapeutic and prophylactic applications of alphavirus vectors. Exp. Rev. Mol. Med. 2008, 10, e33.
7. Khromykh, A.A. Replicon-based vectors of positive strand RNA viruses. Curr. Opin. Mol. Therapy 2000, 2, 555-569.
8. Lundstrom, K. Alphavirus-based vaccines. Curr. Opin. Mol. Ther. 2002, 4, 28-34.
9. Pijlman, G.P.; Suhrbier, A.; Khromykh, A.A. Kunjin virus replicons: An RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin. Biol. Ther. 2006, 6, 135-145.
10. Rayner, J.O.; Dryga, S.A.; Kamrud, K.I. Alphavirus vectors and vaccination. Rev. Med. Virol. 2002, 12, 279-296.
11. Kaisho, T. Pathogen sensors and chemokine receptors in dendritic cell subsets. Vaccine 2012, 30, 7652-7657.
12. Kawai, T.; Akira, S. Toll-like receptor and RIG-I-like receptor signaling. Ann. NY Acad. Sci. 2008, 1143, 1-20.
13. Khoo, J.J.; Forster, S.; Mansell, A. Toll-like receptors as interferon-regulated genes and their role in disease. J. Interferon Cytokine Res. 2011, 31, 13-25.
14. Summerfield, A.; McCullough, K.C. Dendritic cells in innate and adaptive immune responses against influenza virus. Viruses 2009, 1, 1022-1034.
15. Swiecki, M.; McCartney, S.A.; Wang, Y.; Colonna, M. TLR7/9 versus TLR3/MDA5 signaling during virus infections and diabetes. J. Leukoc. Biol. 2011, 90, 691-701.
16. Uematsu, S.; Akira, S. Toll-like receptors and Type I interferons. J. Biol. Chem. 2007, 282, 15319-15323.
17. Ceppi, M.; Ruggli, N.; Tache, V.; Gerber, H.; McCullough, K.C.; Summerfield, A. Double-stranded secondary structures on mRNA induce type 1 interferon (IFN α/β) production and maturation of mRNA-transfected monocyte-derived dendritic cells. J. Gene Med. 2005, 7, 452-465.
18. Bauhofer, O.; Summerfield, A.; Sakoda, Y.; Tratschin, J.D.; Hofmann, M.A.; Ruggli, N. Classical swine fever virus Npro interacts with interferon regulatory factor 3 and induces its proteasomal degradation. J. Virol. 2007, 81, 3087-3096.
19. Ruggli, N.; Bird, B.H.; Liu, L.; Bauhofer, O.; Tratschin, J.D.; Hofmann, M.A. N(pro) of classical swine fever virus is an antagonist of double-stranded RNA-mediated apoptosis and IFN-alpha/beta induction. Virology 2005, 340, 265-276.
20. Ruggli, N.; Summerfield, A.; Fiebach, A.R.; Guzylack-Piriou, L.; Bauhofer, O.; Lamm, C.G.; Waltersperger, S.; Matsuno, K.; Liu, L.; Gerber, M.; et al. Classical swine fever virus can remain virulent after specific elimination of the interferon regulatory factor 3-degrading function of Npro. J. Virol. 2009, 83, 817-829.
21. Bauhofer, O.; Summerfield, A.; McCullough, K.C.; Ruggli, N. Role of double-stranded RNA and Npro of classical swine fever virus in the activation of monocyte-derived dendritic cells. Virology 2005, 343, 93-105.
22. Suter, R.; Summerfield, A.; Thomann-Harwood, L.J.; McCullough, K.C.; Tratschin, J.D.; Ruggli, N. Immunogenic and replicative properties of classical swine fever virus replicon particles modified to induce IFN-alpha/beta and carry foreign genes. Vaccine 2011, 29, 1491-1503.
23. +T cells and antiviral immunity. Immunity 2004, 20, 47-58.
24. Hamdy, S.; Haddadi, A.; Hung, R.W.; Lavasanifar, A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv. Drug Del. Rev. 2011, 63, 943-955.
25. Klippstein, R.; Pozo, D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine 2010, 6, 523-529.
26. Kofler, R.M.; Aberle, J.H.; Aberle, S.W.; Allison, S.L.; Heinz, F.X.; Mandl, C.W. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc. Natl. Acad. Sci. USA 2004, 101, 1951-1956.
27. De Haes, W.; Rejman, J.; Pollard, C.; Merlin, C.; Vekemans, M.; Florence, E.; de Smedt, S.C.; Grooten, J.; Vanham, G.; de Koker, S.; et al. Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses. Nanomedicine (Lond.) 2013, 8, 77-87.
28. De Haes, W.; van Mol, G.; Merlin, C.; de Smedt, S.C.; Vanham, G.; Rejman, J. Internalization of mRNA lipoplexes by dendritic cells. Mol. Pharm. 2012, 9, 2942-2949.
29. McCullough, K.C.; Basta, S.; Knotig, S.; Gerber, H.; Schaffner, R.; Kim, Y.B.; Saalmuller, A.; Summerfield, A. Intermediate stages in monocyte-macrophage differentiation modulate phenotype and susceptibility to virus infection. Immunology 1999, 98, 203-212.
30. Perche, F.; Benvegnu, T.; Berchel, M.; Lebegue, L.; Pichon, C.; Jaffrès, P.-A.; Midoux, P. Enhancement of dendritic cells transfection in vivo and of vaccintion against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 2011, 7, 445-453.
31. Perche, F.; Gosset, D.; Mevel, M.; Miramon, M.L.; Yaouanc, J.J.; Pichon, C.; Benvegnu, T.; Jaffres, P.A.; Midoux, P. Selective gene delivery in dendritic cells with mannosylated and histidylated lipopolyplexes. J. Drug Target 2011, 19, 315-325.
32. Pichon, C.; Midoux, P. Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA. Methods Mol. Biol. 2013, 969, 247-274.
33. McCullough, K.C.; Bassi, I.; Milona, P.; Suter, R.; Thomann-Harwood, L.; Englezou, P.; Démoulins, T.; Ruggli, N. Self-replicating replicon-RNA delivery to dendritic cells by chitosan-nanoparticles for translation in vitro and in vivo. Mol. Ther. Nucleic Acids 2014, 3, e173.
34. Burgdorf, S.; Kurts, C. Endocytosis mechanisms and the cell biology of antigen. Curr. Opin. Immunol. 2008, 20, 89-95.
35. Jensen, P.E. Recent advances in antigen processing and presentation. Nat. Immunol. 2007, 8, 1041-1048.
36. Rocha, N.; Neefjes, J. MHC class II molecules on the move for successful antigen presentation. EMBO J. 2008, 27, 1-5.
37. Thery, C.; Amigorena, S. The cell biology of antigen presentation in dendritic cells. Curr. Opin. Immunol. 2001, 13, 45-51.
38. Van Niel, G.; Wubbolts, R.; Stoorvogel, W. Endosomal sorting of MHC class II determines antigen presentation by dendritic cells. Curr. Opin. Cell Biol. 2008, 20, 437-444.
39. Le Roux, D.; le Bon, A.; Dumas, A.; Taleb, K.; Sachse, M.; Sikora, R.; Julithe, M.; Benmerah, A.; Bismuth, G.; Niedergang, F. Antigen stored in dendritic cells after macropinocytosis is released unprocessed from late endosomes to target B cells. Blood 2011, 119, 95-105.
40. Wykes, M.; Pombo, A.; Jenkins, C.; MacPherson, G.G. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J. Immunol. 1998, 161, 1313-1319.
41. Ackerman, A.L.; Kyritsis, C.; Tampé, R.; Cresswell, P. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat. Immunol. 2004, 6, 107-113.
42. Amigorena, S.; Savina, A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr. Opin. Immunol. 2010, 22, 109-117.
43. Heath, W.; Belz, G.; Behrens, G.M.N.; Smith, C.M.; Forehan, S.P.; Parish, I.A.; Davey, G.M.; Wilson, N.S.; Carbone, F.R.; Villadangos, J.A. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 2004, 199, 9-26.
44. Monu, N.; Trombetta, E.S. Cross-talk between the endocytic pathway and the endoplasmic reticulum in cross-presentationby MHC class I molecules. Curr. Opin. Immunol. 2007, 19, 66-72.
45. Vyas, J.M.; van der Veen, A.G.; Ploegh, H.L. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 2008, 8, 607-618.
46. Geissmann, F.; Manz, M.G.; Jung, S.; Sieweke, M.H.; Merad, M.; Ley, K. Development of monocytes, macrophages and dendritic cells. Science 2010, 327, 656-661.
47. Conner, S.D.; Schmid, S.L. Regulated portals of entry into the cell. Nature 2003, 422, 37-44.
48. Kumari, S.; Mg, S.; Mayor, S. Endocytosis unplugged: Multiple ways to enter the cell. Cell Res. 2010, 20, 256-275.
49. Platta, H.W.; Stenmark, H. Endocytosis and signaling. Curr. Opin. Cell Biol. 2011, 23, 393-403.
50. Sandvig, K.; Pust, S.; Skotland, T.; van Deurs, B. Clathrin-independent endocytosis: Mechanisms and function. Curr. Opin. Cell Biol. 2011, 23, 413-420.
51. Sorkin, A.; von Zastrow, M. Endocytosis and signalling: Intertwining molecular networks. Nat. Rev. Mol. Cell Biol. 2009, 10, 609-622.
52. Belizaire, R.; Unanue, E.R. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc. Natl. Acad. Sci. USA 2009, 106, 17463-17468.
53. Pelkmans, L.; Kartenbeck, J.; Helenius, A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat. Cell Biol. 2001, 3, 473-483.
54. Vazquez-Calvo, A.; Saiz, J.C.; McCullough, K.C.; Sobrino, F.; Martin-Acebes, M.A. Acid-dependent viral entry. Virus Res. 2012, 167, 125-137.
55. McCullough, K.C.; Summerfield, A. Targeting the porcine immune system-Particulate vaccines in the 21st century. Dev. Comp. Immunol. 2009, 33, 394-409.
56. Schalk, J.A.; Mooi, F.R.; Berbers, G.A.; van Aerts, L.A.; Ovelgönne, H.; Kimman, T.G. Preclinical and clinical safety studies on DNA vaccines. Hum. Vaccine 2006, 2, 45-53.
57. Gao, W.; Xiao, Z.; Radovic-Moreno, A.; Shi, J.; Langer, R.; Farokzad, O.C. Progress in siRNA delivery using multifunctional nanoparticles. Methods Mol. Biol. 2010, 629, 53-67.
58. Garcia-Gaumont, C.; Seksek, O.; Grzybowska, J.; Borowski, E.; Bolard, J. Delivery systems for antisense oligonucleotides. Pharmacol. Ther. 2000, 87, 255-277.
59. Howard, K.A. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug Del. Rev. 2009, 61, 710-720.
60. Katas, H.; Alpar, H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release 2006, 115, 216-225.
61. Landesman-Milo, D.; Peer, D. Altering the immune response with lipid-based nanoparticles. J. Control. Release 2012, 161, 600-608.
62. Tamura, A.; Nagasaki, Y. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. Nanomedicine 2010, 5, 1089-1102.
63. Tavernier, G.; Andries, O.; Demeester, J.; Sanders, N.N.; de Smedt, S.C.; Rejman, J. mRNA as gene therapeutic: How to control protein expression. J. Control. Release 2011, 150, 238-247.
64. Yuan, X.; Naquib, S.; Wu, Z. Recent advances of siRNA delivery by nanoparticles. Expert Opin. Drug Deliv. 2011, 8, 521-536.
65. Wasungu, L.; Hoekstra, D. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release 2006, 116, 255-264.
66. Hassane, F.S.; Saleh, A.F.; Abes, R.; Gait, M.J.; Lebleu, B. Cell penetrating peptides: Overview and applications to the delivery of oligonucleotides. Cell Mol. Life Sci. 2010, 67, 715-726.
67. Midoux, P.; Pichon, C.; Yaouanc, J.-J.; Jaffrès, P.-A. Chemical vectors for gene delivery: A current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br. J. Pharmacol. 2009, 157, 166-178.
68. Varkouhi, A.K.; Scholte, M.; Storm, G.; Haisma, H.J. Endosomal escape pathways for delivery of biologicals. J. Control. Release 2011, 151, 220-228.
69. Henriksen-Lacey, M.; Korsholm, K.S.; Andersen, P.; Perrie, Y.; Christensen, D. Liposomal vaccine delivery systems. Exp. Opin. Drug Del. 2011, 8, 505-519.
70. Gonzalez-Rodriguez, M.L.; Rabasco, A.M. Charged liposomes as carriers to enhance the permeation through the skin. Exp. Opin. Drug Del. 2011, 8, 857-871.
71. Jiang, H.-L.; Kim, T.H.; Kim, Y.-K.; Park, I.-Y.; Cho, M.-H.; Cho, C.S. Efficient gene delivery using chitosan-polyethylenimine hybrid systems. Biomed. Mater. 2008, 3, doi:10.1088/1748-6041/3/2/025013.
72. Won, Y.-W.; Lim, K.S.; Kim, Y.-H. Intracellular organelle-targeted non-viral gene delivery systems. J. Control. Release 2011, 152, 99-109.
73. Nakase, I.; Kobayashi, S.; Futaki, S. Endosome-disruptive peptides for improving cytosolic delivery of bioactive macromolecules. Peptide Sci. 2010, 94, 763-770.
74. Hafez, I.M.; Maurer, N.; Cullis, P.R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001, 8, 1188-1196.
75. Kong, Y.; Ruan, L.; Ma, L.; Cui, Y.; Wang, J.M.; Le, Y. RNA interference as a novel and powerful tool in immunopharmacological research. Int. Immunopharm. 2007, 7, 417-426.
76. Davidson, B.L.; McCray, P.B. Current prospects for RNA interference-based therapies. Nat. Rev. Gen. 2011, 12, 329-340.
77. Kim, H.-K.; Wei, H.; Kulkarni, A.; Pogranichniy, R.N.; Thompson, D.H. Effective targeted gene delivery to dendritic cells via synergetic interaction of mannosylated lipid with DOPE and BCAT. Biomacromolecules 2012, 13, 636-644.
78. Mockey, M.; Bourseau, E.; Chandrashekhar, V.; Chaudhuri, A.; Lafosse, S.; le Cam, E.; Quesniaux, V.F.J.; Ryffel, B.; Pichon, C.; Midoux, P. mRNA-based cancer vaccine: Prevention of B16 melanoma progression and metastasis by systemic injection of MART 1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 2007, 14, 802-814.
79. Markov, O.O.; Mironova, N.L.; Maslov, M.A.; Petukhov, I.A.; Morosova, N.G.; Vlassov, V.V.; Zenkova, M.A. Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cell progenitors and their immature offsets. J. Control. Release 2012, 160, 200-210.
80. Debus, H.; Baumhof, P.; Probst, J.; Kissel, T. Delivery of messenger RNA using poly(ethylene imine)-poly(ethylene glycol)-copolymer blends for polyplex formation: Biophysical characterization and in vitro transfection properties. J. Control. Release 2010, 148, 334-343.
81. Rejman, J.; Tavernier, G.; Bavarsad, N.; Demeester, J.; deSmedt, S.C. mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J. Control. Release 2010, 147, 385-391.
82. Tratschin, J.D.; Ruggli, N.; McCullough, K.C. Pestivirus Replicons Providing an RNA-Based Viral Vector System. U.S. Patent US 20110189224 A1, 4th June 2008.
83. Geall, A.J.; Verma, A.; Otten, G.R.; Shaw, C.A.; Hekele, A.; Banerjee, K.; Cu, Y.; Beard, C.W.; Brito, L.A.; Krucker, T.; et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 2012, 109, 14604-14609.
84. Fang, N.; Chan, V.; Mao, H.Q.; Leong, K.W. Interactions of phospholipid bilayer with chitosan: Effect of molecular weight and pH. Biomacromolecules 2001, 2, 1161-1168.
85. Akita, H.; Kogure, K.; Moriguchi, R.; Nakamura, Y.; Higashi, T.; Nakamura, T.; Serada, S.; Fujimoto, M.; Naka, T.; Futaki, S.; Harashima, H. nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. J. Control. Release 2010, 143, 311-317.
86. Brito, L.A.; Chan, M.; Shaw, C.A.; Hekele, A.; Carsillo, T.; Schaefer, M.; Archer, J.; Seubert, A.; Otten, G.R.; Beard, C.W.; et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 2014, doi:10.1038/mt.2014.133.
87. Sharma, R.; Ghasparian, A.; Robinson, J.A.; McCullough, K.C. Synthetic virus-like particles target dendritic cell lipid rafts for rapid endocytosis primarily but not exclusively by macropinocytosis. PLoS One 2012, 7, e43248.
88. Gilleron, J.; Querbes, W.; Zeigerer, A.; Borodovsky, A.; Marsico, G.; Schubert, U.; Manygoats, K.; Seifert, S.; Andree, C.; Stoter, M.; et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 2013, 31, 638-646.
89. Rehman, Z.U.; Hoekstra, D.; Zuhorn, I.S. Mechanism of polyplex-and lipoplex-mediated delivery of nucleic acids: Real-time visualization of transient membrane destabilization without endosomal lysis. ACS Nano 2013, 7, 3767-3777.
90. Suter, R.; Ruggli, N. Institute of Virology and Immunology, Mittelhäusern, Switzerland. Personal communication, 2012.
91. Kuhn, A.N.; Diken, M.; Kreiter, S.; Selmi, A.; Kowalska, J.; Jemielity, J.; Darzynkiewicz, E.; Huber, C.; Tureci, O.; Sahin, U. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther. 2010, 17, 961-971.
92. Pascolo, S. Messenger RNA-based vaccines. Expert Opin. Biol. Ther. 2004, 4, 1285-1294.
93. Petsch, B.; Schnee, M.; Vogel, A.B.; Lange, E.; Hoffmann, B.; Voss, D.; Schlake, T.; Thess, A.; Kallen, K.J.; Stitz, L.; et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 2012, 30, 1210-1216.
94. Strauss, J.H.; Strauss, E.G. The alphaviruses: Gene expression, replication, and evolution. MicroBiol. Rev. 1994, 58, 491-562.
95. Berben-Bloemheuvel, G.; Kasperaitis, M.A.; van Heugten, H.; Thomas, A.A.; van Steeg, H.; Voorma, H.O. Interaction of initiation factors with the cap structure of chimaeric mRNA containing the 5'-untranslated regions of Semliki Forest virus RNA is related to translational efficiency. Eur. J. BioChem. 1992, 208, 581-587.
96. Van Duijn, L.P.; Kasperaitis, M.; Ameling, C.; Voorma, H.O. Additional methylation at the N(2)-position of the cap of 26S Semliki Forest virus late mRNA and initiation of translation. Virus Res. 1986, 5, 61-66.
97. Maruggi, G.; Shaw, C.A.; Otten, G.R.; Mason, P.W.; Beard, C.W. Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity. Virology 2013, 447, 254-264.
98. Rossi, S.L.; Zhao, Q.; O’Donnell, V.K.; Mason, P.W. Adaptation of West Nile virus replicons to cells in culture and use of replicon-bearing cells to probe antiviral action. Virology 2005, 331, 457-470.
99. Kolupaeva, V.G.; Pestova, T.V.; Hellen, C.U. Ribosomal binding to the internal ribosomal entry site of classical swine fever virus. RNA 2000, 6, 1791-1807.
100. Rijnbrand, R.; van der Straaten, T.; van Rijn, P.A.; Spaan, W.J.; Bredenbeek, P.J. Internal entry of ribosomes is directed by the 5' noncoding region of classical swine fever virus and is dependent on the presence of an RNA pseudoknot upstream of the initiation codon. J. Virol. 1997, 71, 451-457.
101. Xu, J.; Luft, J.C.; Yi, X.; Tian, S.; Owens, G.; Wang, J.; Johnson, A.; Berglund, P.; Smith, J.; Napier, M.E.; et al. RNA replicon delivery via lipid-complexed PRINT protein particles. Mol. Pharm. 2013, 10, 3366-3374.